A New Recombinant Bacille Calmette‐Guérin Vaccine Safely Induces Significantly Enhanced Tuberculosis‐Specific Immunity in Human Volunteers | Zendy

Daniel F. Hoft | Zendy; Azra Blazevic | Zendy; Getahun Abate | Zendy; Willem A. Hanekom | Zendy; Gilla Kaplan | Zendy; Jorge Soler | Zendy; Frank Weichold | Zendy; Larry Geiter | Zendy; Jerald Sadoff | Zendy; Marcus A. Horwitz | Zendy

Open Access

A New Recombinant Bacille Calmette‐Guérin Vaccine Safely Induces Significantly Enhanced Tuberculosis‐Specific Immunity in Human Volunteers

Author(s) -

Daniel F. Hoft,

Azra Blazevic,

Getahun Abate,

Willem A. Hanekom,

Gilla Kaplan,

Jorge Soler,

Frank Weichold,

Larry Geiter,

Jerald Sadoff,

Marcus A. Horwitz

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/592450

Subject(s) - tuberculosis , vaccination , mycobacterium tuberculosis , antigen , immunity , recombinant dna , tuberculosis vaccines , immunology , bcg vaccine , mycobacterium bovis , medicine , virology , immune system , microbiology and biotechnology , biology , gene , genetics , pathology

One strategy for improving anti-tuberculosis (TB) vaccination involves the use of recombinant bacille Calmette-Guérin (rBCG) overexpressing protective TB antigens. rBCG30, which overexpresses the Mycobacterium tuberculosis secreted antigen Ag85b, was the first rBCG shown to induce significantly greater protection against TB in animals than parental BCG.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research